LOGIN  |  REGISTER
Cue Biopharma

Acadia Healthcare to Participate in Raymond James 45th Annual Institutional Investors Conference

February 28, 2024 | Last Trade: US$24.53 0.76 3.20

FRANKLIN, Tenn. / Feb 28, 2024 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the Raymond James 45th Annual Institutional Investors Conference, which is being held March 3 - 6, 2024, in Orlando, Florida. In connection with the conference, there will be a webcast of the Company’s presentation available on the Company’s website starting at 10:25 a.m. Eastern Time/11:25 a.m. Central Time on Tuesday, March 5, 2024.

The live webcast of the presentation will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investor Relations” link. A replay of the presentation will also be available on the Company’s website for thirty days.

About Acadia Healthcare Company, Inc.

Acadia is a leading provider of behavioral healthcare services across the United States. As of December 31, 2023, Acadia operated a network of 253 behavioral healthcare facilities with approximately 11,200 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 75,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Assertio

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page